Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development and Manufacturing Organization (CDMO) Market Report 2026

The messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market size has grown rapidly in recent years. It will grow from $8.41 billion in 2025 to $9.68 billion in 2026 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to COVID-19 vaccine programs, growth in biotech startups, limited in house manufacturing capacity, rise in contract manufacturing, rapid mrna platform validation.

The messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market size is expected to see rapid growth in the next few years. It will grow to $17.1 billion in 2030 at a compound annual growth rate (CAGR) of 15.3%. The growth in the forecast period can be attributed to expansion of mrna cancer vaccines, growth in personalized vaccines, higher cdmo partnerships, demand for rapid scale manufacturing, increased pipeline of mrna therapies. Major trends in the forecast period include lipid nanoparticle formulation services, rapid mrna process scale up, integrated fill finish outsourcing, modular vaccine manufacturing suites, end to end mrna development services.

The growing prevalence of infectious and emerging diseases is expected to propel the growth of the mRNA vaccine CDMO market going forward. Infectious and emerging diseases are conditions caused by pathogenic microorganisms that spread rapidly or newly arise due to factors such as environmental changes, urbanization, and increased global connectivity. Rising international travel, higher population density, and interconnected global supply chains have accelerated pathogen transmission, making disease outbreaks more frequent, widespread, and challenging to control. mRNA vaccine CDMOs play a vital role in addressing these challenges by enabling rapid vaccine development, scalable manufacturing, and flexible production needed to respond to evolving infectious threats. mRNA-based technologies require specialized manufacturing infrastructure and technical expertise, leading vaccine developers to depend on contract development and manufacturing organizations to shorten timelines and ensure production readiness during outbreaks. For instance, in May 2024, according to the World Health Organization (WHO), a Switzerland-based United Nations specialized agency for global health, as of 30 April 2024, more than 7.6 million dengue cases were reported globally, including 3.4 million confirmed cases, over 16,000 severe cases, and more than 3,000 deaths. The surge was particularly significant in the Region of the Americas, where reported cases exceeded seven million by April 2024, surpassing the total of 4.6 million cases recorded in 2023. Therefore, the rising prevalence of infectious and emerging diseases is supporting the growth of the mRNA vaccine CDMO market.

Key companies operating in the mRNA vaccine CDMO market are increasingly focusing on advanced innovations such as phase-appropriate GMP mRNA contract development and manufacturing services to accelerate preclinical and IND-enabling development while maintaining regulatory-aligned quality standards and shorter timelines. Phase-appropriate GMP-like mRNA manufacturing refers to a production approach designed to deliver high-quality, regulatory-aware mRNA material suitable for preclinical and early development stages, without the cost and operational complexity associated with full GMP manufacturing. For example, in May 2025, GenScript Biotech Corporation, a China-based global biotechnology reagents and services provider, launched a GMP-like mRNA manufacturing service aimed at supporting preclinical and IND-enabling development. The service delivers high-quality, regulatory-aware mRNA with reduced lead times and lower costs compared to traditional full GMP manufacturing, reflecting the growing demand for flexible, phase-appropriate CDMO solutions in the mRNA vaccine market.

In September 2024, Areterna LLC, a US-based biotech company, partnered with Biomay AG to improve global access to high-quality, cost-effective mRNA vaccine CDMO solutions. Through this partnership, Aeterna and Biomay aim to jointly expand end-to-end mRNA CDMO services across Europe and North America by combining GMP manufacturing capabilities with advanced mRNA design, formulation, and raw material expertise. Biomay AG is an Austria-based contract development and manufacturing organization specializing in mRNA vaccine CDMO services, including GMP manufacturing of mRNA, plasmid DNA, and recombinant proteins for clinical and commercial applications.

Major companies operating in the messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market are Sanofi S.A., Thermo Fisher Scientific Inc., FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Danaher Corporation, Boehringer Ingelheim BioXcellence GmbH & Co. KG, AGC Biologics A/S, Eurofins Scientific SE, Lonza Group AG, BioNTech SE, Samsung Biologics Co. Ltd., WuXi Biologics (Cayman) Inc., Siegfried Holding AG, Recipharm AB, Vetter Pharma International GmbH, CordenPharma GmbH & Co. KG, Ajinomoto Bio-Pharma Services Inc., Novasep Holding S.A.S., Rentschler Biopharma SE, IDT Biologika GmbH, Wacker Biotech GmbH.

Tariffs on bioprocess equipment, specialized reagents, and cold chain packaging materials are influencing the mrna vaccine cdmo market by increasing operational and setup costs. Manufacturing and fill finish segments are most affected where imported reactors, filtration systems, and lipid materials are widely used, particularly across north america and europe. Higher input costs can raise contract service pricing and project budgets. However, tariffs are also driving regional sourcing of raw materials and local biomanufacturing capacity expansion. This supports domestic cdmo facilities and regional vaccine supply chains.

The messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market research report is one of a series of new reports that provides messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market statistics, including messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) industry global market size, regional shares, competitors with a messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market share, detailed messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market segments, market trends and opportunities, and any further data you may need to thrive in the messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) industry. This messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Messenger ribonucleic acid (mRNA) vaccine contract development and manufacturing organizations (CDMOs) are entities that provide outsourced services for the development, scale-up, and commercial production of mRNA-based vaccines. They handle activities such as process development, formulation, analytical testing, fill-finish operations, and regulatory compliance, enabling vaccine developers to accelerate manufacturing while minimizing infrastructure investment and operational complexity.

The key service types of messenger ribonucleic acid (mRNA) vaccine contract development and manufacturing organizations (CDMOs) include process development, manufacturing, analytical and quality control, fill-finish, packaging, and other related services. Process development refers to services that optimize and establish scalable mRNA vaccine production processes for clinical and commercial applications. These services are applied to vaccine types such as COVID-19 vaccines, cancer vaccines, infectious disease vaccines, and others. Operational scales include preclinical, clinical, and commercial stages, with end users being pharmaceutical companies, biotechnology firms, research institutes, and other relevant organizations.

The messenger ribonucleic acid (mRNA) vaccine contract development and manufacturing organization (CDMO) market includes revenues earned by entities through process development services, cell-free transcription optimization, plasmid DNA production services, messenger ribonucleic acid synthesis services, formulation development services, lipid nanoparticle formulation services, and analytical testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.